PersonGen BioTherapeutics (Suzhou) Co., Ltd.
Quick facts
Phase 1 pipeline
- anti-CD7 CAR-pNK cells
- anti-MUC1 CAR-pNK cells
- anti-MUC1 CAR T Cells
- BCMA-CART cells
- CD19 CAR-T cells infusion
- gdT cell injection targeting B7-H3 chimeric antigen receptor
- LV009 Injection Infusion
- γδT Cell infusion agent
- Targeting CD276 CAR T cells
- UTAA09 cells for infusion
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. portfolio CI brief
- PersonGen BioTherapeutics (Suzhou) Co., Ltd. pipeline updates RSS
Related
- Sector hub: All tracked pharma companies